

Sub
cont
C1
to 20 μ l, the dosage form being [comprising] a jet or stream of droplets of treatment fluid, each droplet having an ophthalmologically active compound in suspension or solution and wherein the jet or each droplet [is of a size] has a momentum sufficient to sustain [momentum in] transmission from a delivery device to a target site within an eye, wherein substantially the entire dosage form is delivered to the target site.

Remarks

Claim 1 has been amended. With this amendment, the claims pending are claims 1, 2, and 4-20. Support for the amendments to claim 1 is found in the specification as originally filed. Specifically, support for the volume limitation can be found at page 3, lines 36-37. In addition, support for the "predetermined" limitation can be found at, for example, page 4, line 24, page 6, line 19, and page 8 line 30, where a precise, predetermined amount, e.g., 5 μ L, is administered to a subject in each example. Support for the "delivered" limitation can be found on page 4, lines 6-8.

Applicants respectfully submit that the claims as amended are clearly nonobvious over the reference relied on by the Examiner, U.S. Patent No. 4,158,361 ("Kotuby"). As amended, claim 1 requires a predetermined liquid volume in the form of a jet or stream of droplets and that substantially the entire